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Pathogen alert
Memory T cells, which are generated during an infection, 
migrate through extralymphoid regions and lie in wait to 
mount a swift and strong response after another encounter 
with the pathogen. Recent studies have focused on mem-
ory T cells that permanently reside in the periphery and are 
termed tissue-resident memory cells (TRM cells). They offer 
an attractive target for the development of vaccines, despite 
our general lack of understanding of the mechanisms by 
which small numbers of these cells can protect expansive 
peripheral tissues. In a recent issue of Science, three groups 
reported findings related to the mechanisms governing the 
persistence and protective function of TRM cells. Iijima and 
Iwasaki demonstrated that preexisting CD4 TRM cells in the 
genital mucosa were necessary for full protection from a 
lethal herpes simplex virus 2 infection, and that macrophage-
derived chemokines maintained this cell population in mem-
ory lymphocyte clusters distinct from the circulating cells. 
Schenkel and colleagues demonstrated that CD8 TRM cells 
act as early sensors of infection and generate broad alarming 
functions. Furthermore, Ariotti and colleagues found that trig-
gering of TRM cells—previously created in mice via intraepi-
dermal DNA vaccination—with peptide antigen led to a rapid 
alteration in the transcriptome even before the subsequent 
influx of immune cells. Activation of these cells induced 
numerous factors with broad antiviral and antibacterial activi-
ties. The tissue conditioning that results from activation of TRM 
cells led to enhanced pathogen control from other antigenical-
ly unrelated pathogens. These data demonstrate that this tissue 
conditioning is almost immediate, forms an effective amplifi-
cation system to induce a tissue-wide response, and results in 
antigen-independent protection, which effectively minimizes 
viral escape. Together, these reports demonstrate that TRM cells 
act to bridge the adaptive and innate immune systems by 
triggering a state of tissue-wide pathogen alert and, as such, 
provide an attractive target for the design of strategies to halt 
pathogens before infection establishment. (Science 346:40–1, 
2014; Science 346:93–8, 2014; Science 346:98–101, 2014; 
Science 346:101–5, 2014) Selected by L. Beck
Targeting the linchpin
The proinflammatory IL-17A has been suggested to be the mas-
ter cytokine that functions in the pathogenesis of psoriasis to 
stimulate keratinocytes to secrete chemokines and inflamma-
tory molecules, which recruit additional inflammatory cells. 
Results of previous clinical trials of IL-17A inhibitors support 
the notion that this cytokine is crucial in other immune-medi-
ated disorders as well. On the tail of basic research and early 
clinical studies, Langley and colleagues conducted two ran-
domized phase III trials (a two-dose comparison in ERASURE 
and a full-year investigative comparison in FIXTURE) to assess 
the efficacy and safety of secukinumab, a recombinant fully 
humanized immunoglobulin G1κ monoclonal antibody that 
neutralizes IL-17A. Secukinumab was associated with a rapid 
reduction in disease symptoms, higher PASI 75 rates, and high 
response rates in a majority of patients through week 52. In 
addition, secukinumab was superior to the tumor necrosis fac-
tor etanercept. Thus, secukinumab proved to be effective for 
treating psoriasis in both studies, supporting the importance 
of IL-17A in psoriasis pathogenesis and as a treatment target. 
(N Engl J Med 371:326–38, 2014) Selected by T. Schwarz
Two is better than one
Inhibition of the MAPK pathway with BRAF inhibitors (dab-
rafenib) improves the survival of metastatic melanoma patients 
who harbor the BRAF V600 mutation; however, the majority of 
these patients develop resistance to treatment via reactivation 
of the MAPK pathway. Previous preclinical and phase II studies 
indicated that inhibition of this signaling pathway using both 
BRAF and MEK inhibitors (trametinib) delayed the emergence 
of resistance and decreased the development of cutaneous 
hyperproliferative lesions, which often occur with MAPK sig-
naling reactivation. Long and colleagues conducted a double-
blind, randomized phase III study to determine the efficacy of a 
combination of dabrafeib and trametinib as a first-line therapy 
of 423 metastatic melanoma patients with a BRAF V600E or 
V600K mutation. This combination treatment induced a 25% 
relative reduction in the risk of disease progression and resulted 
in a significantly higher overall response rate in these patients 
than in patients treated with dabrafenib alone. These findings 
demonstrate that inhibition of the MAPK pathway at two dis-
tinct points decreases the risk of progression and thereby delays 
resistance in metastatic melanoma patients. (N Engl J Med 
371:1877–88, 2014) Selected by B.A. Gilchrest
Risky business
Telomere length, which decreases with age as well as after 
exposure to UV radiation and smoking, has been associated 
with risk of age-associated diseases, including cancers. For mel-
anoma, longer telomeres have been associated with increased 
risk and increased number of nevi, which is a significant risk 
factor for melanoma development. Although genetic variants—
single-nucleotide polymorphisms (SNPs)—have been identi-
fied in association with telomere length in a meta-analysis, Iles 
and colleagues recently investigated these variants in 11,108 
cases and 13,933 controls in a genome-wide association study 
of melanoma. Four of the seven SNPs were significantly associ-
ated with melanoma risk based on a calculated genetic score 
that predicts telomere length. These results support the hypoth-
esis that genetic factors that influence telomere length have a 
strong effect on melanoma risk, with a longer telomere length 
predisposing melanoma. (J Natl Cancer Inst 106:dju267, 2014) 
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